Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares of the company’s stock, valued at $53,947,690.28. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Helen Torley also recently made the following trade(s):

• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $78.64, for a total value of $786,400.00.
• On Monday, December 1st, Helen Torley sold 16,569 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48.
• On Tuesday, November 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00.

Halozyme Therapeutics Stock Up 3.6%

NASDAQ:HALO opened at $81.23 on Friday. The company has a market cap of $9.55 billion, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 0.33 and a beta of 0.97. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $81.36. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The stock has a fifty day simple moving average of $69.43 and a 200-day simple moving average of $69.08.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of the company. Mizuho Markets Americas LLC raised its stake in shares of Halozyme Therapeutics by 270.8% during the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after acquiring an additional 926,526 shares in the last quarter. LSV Asset Management increased its position in shares of Halozyme Therapeutics by 2.8% during the fourth quarter. LSV Asset Management now owns 1,301,055 shares of the biopharmaceutical company’s stock worth $87,561,000 after purchasing an additional 35,028 shares in the last quarter. Pzena Investment Management LLC lifted its holdings in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Pzena Investment Management LLC now owns 4,278 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 171 shares during the last quarter. Global Retirement Partners LLC boosted its position in shares of Halozyme Therapeutics by 44.8% in the 4th quarter. Global Retirement Partners LLC now owns 2,046 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 633 shares in the last quarter. Finally, Twin Capital Management Inc. purchased a new position in Halozyme Therapeutics during the 4th quarter worth $758,000. 97.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HALO has been the subject of several research analyst reports. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Leerink Partners raised Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price for the company in a research report on Tuesday, October 14th. Citizens Jmp increased their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Morgan Stanley cut their price target on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $78.80.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised 2025 and 2026 revenue guidance, prompting fresh valuation attention and supporting higher expectations for revenue growth going forward. This is a primary driver of the intraday uptick. A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance
• Positive Sentiment: Analysts have been revising near-term earnings and EPS forecasts upward (including a raised Q1 EPS estimate), which supports investor sentiment and higher price targets. Upward analyst revisions tend to lift momentum in the shares. Research Analysts Offer Predictions for HALO FY2025 Earnings
• Positive Sentiment: Recent quarterly results (Nov. 3) showed an EPS and revenue beat and strong margins/ROE, reinforcing the thesis that ENHANZE-driven royalties and commercial growth can sustain higher profitability. That fundamental strength underpins current multiple expansion. MarketBeat Halozyme summary and earnings recap
• Neutral Sentiment: Longer-term thematic coverage notes medtech companies seeing multi‑decade growth opportunities; if Halozyme is included in that narrative it could support longer-duration investor interest but is more thematic than immediately catalytic. This medical technology leader sees growth into the 2040s
• Neutral Sentiment: Institutional ownership remains very high (~98%) and analyst ratings are mixed (buys, holds, one sell). That concentration can amplify moves but also limits free float liquidity. MarketBeat institutional & analyst snapshot
• Negative Sentiment: CEO Helen Torley has sold multiple blocks of shares recently (10,000 shares on Feb 5 at ~$78.64; prior sales of 20,000 at ~$76.12 and other sales in 2025/2024). Insider selling can create short‑term pressure or raise governance questions for some investors. Insider Selling: Halozyme Therapeutics CEO Sells 10,000 Shares

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.